Globe Newswire

LONDON, Ontario, June 10, 2024 (GLOBE NEWSWIRE) -- London Research & Pharmaceuticals presented notable pre-clinical data about its lead compound, LRP-661, also known as Cannabidiol Sulphate (CBDS), at the Seventeenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII) conference in Madrid, Spain, May 5th to May 8th, 2024.

LRP-661’s data highlights its superior safety, efficacy, bioavailability, and PK in multiple species. Furthermore, LRP-661’s oral... (continue reading...)

LONDON, Ontario, June 10, 2024 (GLOBE NEWSWIRE) -- London Research & Pharmaceuticals presented notable pre-clinical data about its lead compound, LRP-661, also known as Cannabidiol Sulphate (CBDS), at the Seventeenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII) conference in Madrid, Spain, May 5th to May 8th, 2024.

LRP-661’s data highlights its superior safety, efficacy, bioavailability, and PK in multiple species. Furthermore, LRP-661’s oral... (continue reading...)

Pineapple Energy Engaged With Firm Known For Helping To Ensure Fairness In Free Trading Markets

MINNETONKA, Minn., June 10, 2024 (GLOBE NEWSWIRE) -- Pineapple Energy Inc. (“Pineapple”), a leading provider of sustainable solar energy and backup power to households and small businesses, is announcing that is investigating potential purposeful short selling of its stock, and has retained well-known analytics firm, Shareholder Intelligence Services, LLC ("ShareIntel").

Salisbury, MD, June 10, 2024 (GLOBE NEWSWIRE) -- Perdue Farms, a fourth-generation, family-owned U.S. food and agricultural company, is pleased to announce the appointment of Perry Aulie as President of Perdue AgriBusiness, effective July 1, 2024. Aulie succeeds Scott Fredericksen, who is retiring from the Maryland-based company.

Aulie, currently the Senior Vice President of Value-Added Products, has been with Perdue AgriBusiness since 2019. Under his leadership,... (continue reading...)

• Investigational roflumilast cream 0.15% showed continued improvements in the signs and symptoms of AD, including itch, through 56 weeks of treatment
• 66.2% of participants treated with once-daily roflumilast cream 0.15% in both the 4-week parent study and the 52-week open label extension achieved a 75% improvement in Eczema Area and Severity Index (EASI-75) at Week 56
• For participants who achieved disease clearance and switched to proactive twice weekly application of... (continue reading...)